In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity

[1]  A. Almulla,et al.  Adverse childhood experiences and recent negative events activate immune and growth factor pathways, which are associated with first episode major depression and suicidal behaviours , 2023, medRxiv.

[2]  A. Sughondhabirom,et al.  Effects of recurrence of illness and adverse childhood experiences on effector, cytotoxic, and regulatory T cells, and cannabinoid receptor-bearing B cells in major depression, an autoimmune disorder. , 2023, medRxiv.

[3]  A. Sughondhabirom,et al.  T cell activation via the CD40 ligand and transferrin receptor and deficits in T regulatory cells are associated with major depressive disorder and severity of depression , 2023, medRxiv.

[4]  Michael Maes,et al.  T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors , 2023, medRxiv.

[5]  K. Plaimas,et al.  Adverse childhood experiences and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviors and the phenome of major depression: towards enterotypic-phenotypes. , 2023, Acta neuropsychiatrica.

[6]  Michael Maes,et al.  Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron , 2022, medRxiv.

[7]  Michael Maes,et al.  Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome Features , 2022, medRxiv.

[8]  Michael Maes,et al.  Chronic fatigue and affective symptoms in acute and long COVID are attributable to immune‐inflammatory pathways , 2022, Psychiatry and clinical neurosciences.

[9]  A. Almulla,et al.  Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study , 2022, Molecular Psychiatry.

[10]  M. Yaqoob,et al.  A systematic review and meta-analysis of the evidence on inflammation in depressive illness and symptoms in chronic and end-stage kidney disease. , 2022, Psychological medicine.

[11]  S. Nunes,et al.  Research and Diagnostic Algorithmic Rules (RADAR) for mood disorders, recurrence of illness, suicidal behaviors, and the patients lifetime trajectory , 2022, medRxiv.

[12]  M. Kubera,et al.  Lowered Quality of Life in Long COVID Is Predicted by Affective Symptoms, Chronic Fatigue Syndrome, Inflammation and Neuroimmunotoxic Pathways , 2022, International journal of environmental research and public health.

[13]  M. Kubera,et al.  Lowered quality of life in Long COVID is strongly predicted by affective symptoms and chronic fatigue syndrome which are associated with inflammatory processes during the acute infectious phase and consequent neuroimmunotoxic pathways. , 2022, medRxiv.

[14]  J. García-Verdugo,et al.  Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease , 2022, Advanced healthcare materials.

[15]  H. Al-Hakeim,et al.  The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium , 2022, medRxiv.

[16]  M. Kubera,et al.  Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles , 2022, Cells.

[17]  M. Cantorna,et al.  CCL27 is a crucial regulator of immune homeostasis of the skin and mucosal tissues , 2022, iScience.

[18]  M. Maes,et al.  A Causal-Pathway Phenotype of Chronic Fatigue Syndrome due to Hemodialysis in Patients with End-Stage Renal Disease. , 2022, CNS & neurological disorders drug targets.

[19]  K. Plaimas,et al.  In Vitro Effects of Cannabidiol on Activated Immune–Inflammatory Pathways in Major Depressive Patients and Healthy Controls , 2022, Pharmaceuticals.

[20]  Michael Maes.  Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self , 2022, Journal of personalized medicine.

[21]  S. Sirivichayakul,et al.  Delirium due to hip fracture is associated with activated immune-inflammatory pathways and a reduction in negative immunoregulatory mechanisms , 2022, BMC Psychiatry.

[22]  P. Gałecki,et al.  The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach , 2022, medRxiv.

[23]  M. Serapide,et al.  TRAIL-R Deficient Mice Are Protected from Neurotoxic Effects of Amyloid-β , 2021, International journal of molecular sciences.

[24]  Michael Maes,et al.  Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach , 2021, Journal of Affective Disorders.

[25]  Hui-Rong Jiang,et al.  Increased Levels of IL-16 in the Central Nervous System during Neuroinflammation Are Associated with Infiltrating Immune Cells and Resident Glial Cells , 2021, Biology.

[26]  Michael Maes,et al.  Intersections between Copper, β-Arrestin-1, Calcium, FBXW7, CD17, Insulin Resistance and Atherogenicity Mediate Depression and Anxiety Due to Type 2 Diabetes Mellitus: A Nomothetic Network Approach , 2021, medRxiv.

[27]  S. Sirivichayakul,et al.  In schizophrenia, chronic fatigue syndrome- and fibromyalgia-like symptoms are driven by breakdown of the paracellular pathway with increased zonulin and immune activation-associated neurotoxicity. , 2021, medRxiv.

[28]  M. Maes,et al.  Adverse childhood experiences combined with emotional and physical abuse by the partner predict antenatal depression. , 2021, Journal of affective disorders.

[29]  M. Maes,et al.  Construction of a nitro-oxidative stress-driven, mechanistic model of mood disorders: a nomothetic network approach. , 2020, Nitric oxide : biology and chemistry.

[30]  M. Maes,et al.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach , 2020, Metabolic Brain Disease.

[31]  S. Madigan,et al.  Depression and Inflammation Among Children and Adolescents: A Meta-analysis , 2020, Biological Psychiatry.

[32]  P. Hsu,et al.  TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases , 2020, Cellular & Molecular Immunology.

[33]  M. Maes,et al.  Increased Oxidative Stress Toxicity and Lowered Antioxidant Defenses in Temporal Lobe Epilepsy and Mesial Temporal Sclerosis: Associations with Psychiatric Comorbidities , 2020, Molecular Neurobiology.

[34]  M. Maes,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: From Pathophysiological Insights to Novel Therapeutic Opportunities. , 2019, Pharmacological research.

[35]  M. Maes,et al.  Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress , 2018, Molecular Neurobiology.

[36]  Feng Li,et al.  Regulatory T cells were recruited by CCL3 to promote cryo-injured muscle repair. , 2018, Immunology letters.

[37]  J. Buri.  Negative Life Events Scale for Students (NLESS). , 2018 .

[38]  M. Maes,et al.  Early Life Trauma Predicts Affective Phenomenology and the Effects are Partly Mediated by Staging Coupled with Lowered Lipid-Associated Antioxidant Defences , 2018, bioRxiv.

[39]  M. Rietschel,et al.  Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression , 2018, bioRxiv.

[40]  M. Maes,et al.  The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder , 2018, Molecular Neurobiology.

[41]  N. Schmitz,et al.  The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: A systematic review and meta-analysis , 2018, Experimental Gerontology.

[42]  M. Maes,et al.  In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study , 2018, Neurotoxicity Research.

[43]  S. Leighton,et al.  Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis , 2017, Molecular Psychiatry.

[44]  A. Carvalho,et al.  Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies , 2017, Acta psychiatrica Scandinavica.

[45]  R. Cowan,et al.  Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16) , 2016, The Journal of Biological Chemistry.

[46]  A. Danese,et al.  Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. , 2016, The lancet. Psychiatry.

[47]  J. Schwarz,et al.  An investigation into the effects of antenatal stressors on the postpartum neuroimmune profile and depressive-like behaviors , 2016, Behavioural Brain Research.

[48]  M. Inglot,et al.  Depression and neuroticism in patients with chronic hepatitis C: correlation with peripheral blood mononuclear cells activation. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[49]  M. Maes,et al.  Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? , 2014, Expert opinion on therapeutic targets.

[50]  M. Berk,et al.  The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs) , 2014, Molecular Neurobiology.

[51]  M. Maes,et al.  Biological phenotypes underpin the physio‐somatic symptoms of somatization, depression, and chronic fatigue syndrome , 2014, Acta psychiatrica Scandinavica.

[52]  L. Crofford,et al.  Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[53]  M. Maes,et al.  In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. , 2013, Journal of affective disorders.

[54]  M. Dragunow,et al.  M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia , 2013, Journal of Neuroinflammation.

[55]  M. Maes,et al.  In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS‐damaged neoepitopes , 2013, Acta psychiatrica Scandinavica.

[56]  G. Morris,et al.  Increased nuclear factor-κB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). , 2012, Medical hypotheses.

[57]  M. Berk,et al.  Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome. , 2012, Medical hypotheses.

[58]  M. Geffard,et al.  IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression , 2012, Metabolic Brain Disease.

[59]  M. Berk,et al.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors , 2012, Inflammopharmacology.

[60]  M. Kubera,et al.  Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[61]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[62]  Michael Maes.  Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[63]  J. Scher,et al.  The Anti-Inflammatory Effects of Prostaglandins , 2009, Journal of Investigative Medicine.

[64]  J. Roth,et al.  CCL3/MIP-1α is not involved in the LPS-induced fever and its pyrogenic activity depends on CRF , 2009, Brain Research.

[65]  David C. Ford,et al.  Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[66]  G. Souza,et al.  CCL3/Macrophage inflammatory protein-1α induces fever and increases prostaglandin E2 in cerebrospinal fluid of rats: Effect of antipyretic drugs , 2006, Brain Research.

[67]  C. Gottfries,et al.  A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). , 2002, Journal of psychosomatic research.

[68]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[69]  R. Kurth,et al.  Interleukin‐16 stimulates the expression and production of pro‐inflammatory cytokines by human monocytes , 2000, Immunology.

[70]  N. Copeland,et al.  CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[71]  K. Kendler,et al.  Causal relationship between stressful life events and the onset of major depression. , 1999, The American journal of psychiatry.

[72]  D. Williamson,et al.  Relationship of Childhood Abuse and Household Dysfunction to Many of the Leading Causes of Death in Adults: The Adverse Childhood Experiences (ACE) Study. , 1998, American journal of preventive medicine.

[73]  M. Maes,et al.  The monocyte-T-lymphocyte hypothesis of major depression , 1995, Psychoneuroendocrinology.

[74]  R. D. Myers,et al.  Macrophage inflammatory protein-1: Unique action on the hypothalamus to evoke fever , 1990, Brain Research Bulletin.

[75]  E. Paykel,et al.  Life Events and Social Support in Puerperal Depression , 1980, British Journal of Psychiatry.

[76]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[77]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[78]  V. Hamilton.  Eysenck' s theories of anxiety and hysteria; a methodological critique. , 1959, British journal of psychology.

[79]  Guihong Ye,et al.  CGRP modulates the pathogenetic process of psoriasis via promoting CCL27 secretion in a MAPK- and NF-úB signaling pathway-dependent manner , 2017 .

[80]  Goran Arbanas.  Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[81]  M. Maes,et al.  Role of Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways in the Etiology of Depression: Therapeutic Implications , 2013, CNS Drugs.

[82]  V. Preedy,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2008 .

[83]  P. Spinhoven,et al.  Negative life events and depression in elderly persons: a meta-analysis. , 2002, The journals of gerontology. Series B, Psychological sciences and social sciences.